#### **TITLE PAGE**

- 1 2 **Full-length title:** Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major 3 4 SARS-CoV-2 variants in a chronically infected immunocompromised patient 5 Short title (for the running head): 6 SARS-CoV-2 recombinations between variants during chronic infection Author list: Emilie BUREL<sup>1,2 ¥</sup>, Philippe COLSON<sup>1,2,3 ¥</sup>, Jean-Christophe LAGIER<sup>1,2,3</sup>, 7 Anthony LEVASSEUR<sup>1,2</sup>, Marielle BEDOTTO<sup>1</sup>, Philippe LAVRARD<sup>1,2,3</sup>, Pierre-8 Edouard FOURNIER<sup>1,2,4</sup>, Bernard LA SCOLA<sup>1,2,3</sup>\*, Didier RAOULT<sup>1,2</sup>\* 9 Affiliations: <sup>1</sup> IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, 10 France; <sup>2</sup> Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes 11 12 Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille, France; <sup>3</sup> Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005 13 Marseille, France; <sup>4</sup> Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), 14 Vecteurs - Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean 15 16 Moulin, 13005 Marseille, France. 17 <sup>¥</sup>Contributed equally 18 \* Corresponding author: Didier Raoult, IHU Méditerranée Infection, 19-21 boulevard Jean 19 Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email: 20 didier.raoult@gmail.com: Bernard La Scola. IHU Méditerranée Infection, 19-21 boulevard 21 Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email: bernard.la-scola@univ-amu.fr. 22 23 Key words: SARS-CoV-2; variant; recombination; chronic infection; immunosuppression
- 24 Word counts: abstract. 212: text. 2.353
- 25 Figures: 3; Tables: 2; References: 48; Supplementary Material: Supplementary Methods,
- Rest this Figure S1, and Table S1 has not been certified by peer review and should not be used to guide clinical practice. 26

27

### ABSTRACT

28

29 Genetic recombination is a major evolutionary mechanism among RNA viruses, and it 30 is common in coronaviruses, including those infecting humans. A few SARS-CoV-2 31 recombinants have been reported to date whose genome harbored combinations of mutations 32 from different mutants or variants, but a single patient's sample was analyzed, and the virus 33 was not isolated. Here, we re-port the gradual creation of a hybrid genome of B.1.160 and 34 Alpha variants in a lymphoma patient chronically infected for 14 months, and we isolated the 35 recombinant virus. The hybrid genome was obtained by next-generation sequencing, and 36 recombination sites were confirmed by PCR. This consisted of a parental B.1.160 backbone 37 interspersed with two fragments, including the spike gene, from an Alpha variant. Analysis of 38 seven sequential samples from the patient decoded the recombination steps, including the 39 initial infection with a B.1.160 variant, then a concurrent infec-tion with this variant and an 40 Alpha variant, the generation of hybrid genomes, and eventually the emergence of a 41 predominant recombinant virus isolated at the end of the patient's follow-up. This case 42 exemplifies the recombination process of SARS-CoV-2 in real life, and it calls for 43 intensifying genomic surveillance in patients coinfected with different SARS-CoV-2 variants, 44 and more gener-ally with several RNA viruses, as this may lead to the creation of new 45 viruses. 46

#### 48

#### TEXT

49

#### **INTRODUCTION** 50

51 A major evolutionary mechanism of RNA viruses is genetic recombination [1,2]. Recombinations are extremely common in coronaviruses and have been implicated in the 52 emergence of several genotypes, including endemic human coronaviruses [3-6]. The in-53 54 volvement of genetic recombination in the origin of SARS-CoV-2 is also suspected [7]. 55 Regarding SARS-CoV-2, coinfection in the same patient with distinct variants has been 56 reported [8-14]. In addition, several studies have described or suspected genetic recom-57 binations for this virus [10,13-14,15-25]. However, most of these recombinants relied solely 58 on the coexistence of signature mutations of different SARS-CoV-2 variants in ge-nomes 59 obtained from a single patient's sample, and they were not isolated in culture. Since January 60 2020, our laboratory has screened more than one million respiratory specimens for SARS-61 CoV-2 infection by real-time reverse transcription-PCR (qPCR) without interruption or 62 limited capacity including for all patients sampled in our institute and in the Marseille public 63 hospitals [26,27]. This has provided us with sequential samples from multiple patients, and 64 enabled us to detect reinfections, and prolonged or even chronic infections in severely 65 immunocompromised patients [28-30]. Here, we re-port the gradual creation of a recombinant 66 SARS-CoV-2 involving two variants in a lymphoma patient chronically infected over a period 67 of 14 months, and the isolation of the recombinant virus in culture.

68

#### RESULTS 69

#### 70 Chronic SARS-CoV-2-infection in a severely immunocompromised patient

71 An immunocompromised adult patient had an uncontrolled SARS-CoV-2 infection for 72 14 months until death (Supplementary Material: Supplementary Methods and Results). This 73 patient had been previously diagnosed with mixed Hodgkin and follicular lymphoma. In

2020, the patient developed severe SARS-CoV-2-associated pneumonia as diagnosed
virologically by qPCR. Despite clinical improvement, viral clearance did not occur as SARSCoV-2 RNA remained detectable by qPCR on most nasopharyngeal samples collected until
patient's death. qPCR was negative at Month 5 of diagnosis but positive when re-tested at
Month 7, and then only transiently negative for ≤3 days.

- 79 Evidence of hybrids of variants
- 80 After 14 months of infection, we identified a virus whose genome was a hybrid of two

81 known variants, B.1.160 [according to Pangolin lineage (https://cov-

82 lineages.org/resources/pangolin.html) [31]] [a.k.a. Nextstrain clade (https://nextstrain.org/)

83 [32] 20A.EU2, or Marseille-4 [27]] and Alpha [according to the WHO denomination

84 (https://www.who.int/fr/activities/tracking-SARS-CoV-2-variants) (a.k.a. 20I or B.1.1.7)]

85 (Figure 1; Figure 2).

86 This hybrid genome was obtained from the respiratory samples by next-generation 87 sequencing, as previously described [27]. In addition, the hybrid virus was isolated in culture, 88 as previously described [33]. The hybrid genome sequence consisted of a B.1.160 variant 89 matrix, of which two regions, the first one being located at the 5' tip of the ge-nome and 90 containing synonymous mutation C913U and the second one spanning from positions 17,109-91 18,877 to positions 25,710-27,972, were replaced by those of an Alpha variant (Figure 1; 92 Figure 2; Supplementary Material: Figure S1). All eight signature mu-tations of the Alpha variant were detected in the spike gene in the absence of the S477N mutation that is a 93 94 signature of the B.1.160 variant. Nucleotide diversity at the 35 positions harboring signature 95 mutations of the Alpha or B.1.160 variants was low [mean (±standard deviation) value of 96 3.1±6.8%] (Figure 2; Supplementary Material: Figure S1), indicating that the hybrid content 97 of the genome was not explained by a co-infection by the two variants or by contamination. 98 These findings indicated that this mosaic genome was the result of recombinations between 99 parental genomes of the B.1.160 and Alpha variants.

#### 100 Genome of the initial virus

101 By analyzing the sequential samples available from this patient, we were able to 102 determine that he was first infected with the B.1.160 variant, which was epidemic at the time 103 of diagnosis of his infection during summer 2020. This variant predominated in our region 104 from August 2020 until January 2021 and was replaced by the Alpha variant that emerged in December 2020 [27]. SARS-CoV-2 could not be isolated retrospectively from this sample, 105 106 but its genome was typical of a B.1.160 variant and displayed no significant nucleotide 107 diversity (mean, 0.2±0.5%). It was classified by phylogeny as a B.1.160 variant (Figure 3). 108 Unfortunately, although SARS-CoV-2 qPCR was still positive in another laboratory at Month 109 4 post-diagnosis, the sample was unavailable, and we were not able to verify that only this 110 virus had persisted and that there was no co-infection with an Alpha variant at this time. Thus, 111 we did not obtain the genome and an isolate of the Alpha variant. The closest sample in time 112 to the initial one dated from Month 8, and it already demonstrated a mosaicism between 113 genomes of B.1.160 and Alpha variants (Figure 1, Figure 2).

#### 114 Steps in creation of the recombinant

115 We used three procedures to characterize the different recombination steps by 116 analyzing seven sequential respiratory samples collected from the patient (Tables 1, 2). First, 117 sequencing from the respiratory samples of the viral genomes; second, sequencing from the 118 respiratory samples of PCR products overlapping the putative recombination sites; and third, 119 viral culture with sequencing of the genomes of the isolates. These approaches allowed us to 120 evidence that several viruses and recombinant forms had coexisted in the sequential samples, 121 as signature mutations of the two variants were co-detected at multiple positions, with a 122 nucleotide diversity that reached high levels and evolved over time (Figure 2; Supplementary 123 Material: Supplementary Results and Figure S1). We observed an evolution towards the 124 genome sequence of the recombinant virus that predominated at the end of the patient's 125 follow-up, following recombination events at three sites between parental genomes of B.1.160

and Alpha variants, with a low level of nucleotide diversity observed at that time at the

127 positions harboring signature mutations of these variants.

128

#### 129 DISCUSSION

130 We highlight here in an immunocompromised lymphoma patient who received several 131 treatments the presence after 14 months of infection of a hybrid virus of two known variants. 132 B.1.160 and Alpha, which successively predominated in our region during the period during 133 which this patient was followed-up [35, 27]. The first evidence of a hybrid genome was 134 obtained 8 months after the diagnosis of infection by the B.1.160 variant, and the absence of 135 available samples covering this period did not allow us to date the superinfection by the 136 Alpha variant. The signature mutations of the Alpha variant observed in the hybrid genomes 137 between 8 and 14 months cannot have occurred randomly considering their number and 138 distribution along the genome and their majority presence, and their location indicates 139 recombinations in three regions. In addition, genomic analyses carried out for sequential 140 respiratory samples and viral cultures demonstrate the successive presence of several viruses 141 with hybrid genomes, one of them having established itself in this patient and remaining the 142 one that continued circulating until his death.

143 We believe that this observation, which sheds light on the recombination mecha-nism 144 of RNA viruses, is significant, and to our knowledge this is the first one describing, through 145 the analysis of sequential samples over more than a year, the creation of a re-combinant 146 SARS-CoV-2 and the isolation of the recombinant virus in culture. Sixteen interlineage 147 recombinants between the Alpha variant and non-Alpha viruses were reported in 2021 in the 148 UK, of 279,000 genomes analyzed [8]. In addition, 1,175 (0.2%) pu-tative recombinant 149 genomes were identified among 537,360 genomes, and it was reported that up to 5% of 150 SARS-CoV-2 that circulated in the USA and UK might be recombinants [18]. Moreover, the 151 number of cases of detection of recombinant genomes is growing [10,13-14,15-25]. Recently,

152 coronaviruses have been reported to be able to integrate se-quences putatively from insects 153 [36]. Such natural mosaicisms in these viruses make it possible to understand the emergence 154 of RNA viruses and should lead to a strengthening of genomic surveillance in patients 155 presenting with coinfections by several RNA viruses, as is observed in patients infected with 156 several respiratory viruses including SARS-CoV-2, endemic human coronaviruses, influenza 157 viruses, or rhinoviruses [37]. Such infectious episodes could perhaps lead to the creation of 158 new emerging viruses, as has been for instance reported for enteroviruses of humans and great 159 apes [38].

160

#### 161 MATERIALS AND METHODS

#### 162 SARS-CoV-2 genome sequencing

163 SARS-CoV-2 genome sequencing was performed as previously described. Briefly, 164 viral RNA was extracted from 200 µL of nasopharyngeal swab fluid using the EZ1 Virus 165 Mini kit v2.0 on an EZ1 Advanced XL instrument (Qiagen, Courtaboeuf, France) or using the 166 MagMax Viral/Pathogen Nucleic Acid Isolation kit on the KingFisher Flex system (Thermo 167 Fisher Scientific, Waltham, MA, United States), following the manufacturer's instructions. 168 SARS-CoV-2 genome sequences were obtained by next-generation sequencing with various 169 procedures with the Illumina COVIDSeq protocol on a NovaSeq 6000 instrument (Illumina 170 Inc.), or by multiplex PCR with ARTIC nCoV-2019 V3 Panel primers (IDT, Coralville, IA, USA) combined with the Oxford Nanopore technology (ONT) on a GridION instrument 171 172 (Oxford Nanopore Technologies Ltd., Oxford, United Kingdom), as previously described 173 [27,14]. After its extraction, viral RNA was reverse-transcribed according to the COVIDSeq 174 protocol (Illumina Inc.) or using the LunaScript RT SuperMix kit (New England Biolabs) 175 when performing next-generation sequencing with the Nanopore technology, following the 176 manufacturer's recommendations.

177 Genome analysis

178	After using the Nanopore technology combined with the ARTIC protocol, fastq files
179	were processed using the ARTIC field bioinformatics pipeline (ARTIC-nCoV-
180	bioinformaticsSOP-v1.1.0; https://github.com/artic-network/fieldbioinformatics), as
181	previously described [27,14]. NGS reads were basecalled using Guppy (4.0.14) and aligned to
182	the genome of the Wuhan-Hu-1isolate, GenBank accession No. MN908947.3, using
183	minimap2 (v2.17-r941) (https://github.com/lh3/ minimap2) [39]. The ARTIC tool align_trim
184	was used to softmask primers from read alignment and cap sequencing depth at a maximum
185	of 400-fold coverage. Consensus-level variant candidates were identified using a threshold of
186	70% and the Medaka (v.0.11.5) workflow developed by ARTIC (https://github.com/artic-
187	network/artic-ncov2019). From the unique sequence obtained with the ARTIC-Nanopore
188	technology, a sorted bam file was loaded on the CLC Genomics workbench v7 software and a
189	tsv file was then exported. NovaSeq reads were basecalled using the Dragen Bcl Convert
190	pipeline (v3.9.3; https://emea.support.illumina.com/sequencing/sequencing_software/bcl-
191	convert.html (Illumina Inc.)). Mapping was carried out on the Wuhan-Hu-1 isolate genome
192	with the bwa-mem2 tool (v2.2.1; https://github.com/bwa-mem2/bwa-mem2) and was cleaned
193	with Samtools (v1.13; https://www.htslib.org/) [40]. Variant calling was performed with
194	freebayes (v1.3.5; https://github.com/freebayes/freebayes) [41] and consensus genomes were
195	built with Bcftools (v1.13; https://samtools.github.io/bcftools/bcftools.html). Freebayes
196	results were filtered with a threshold of 70% for the majority nucleotide. A tsv file was
197	generated using an in-house Python script. The clade was designated at the consensus level
198	with the Nextclade online tool (https://clades.nextstrain.org/) [42,32] and an in-house Python
199	script allowed detection of variants and hybrids of variants. At the sub-consensus level,
200	variant frequencies compared to the Wuhan-Hu-1 isolate genome were calculated from tsv
201	files. Nucleotide diversity at genomic positions was calculated using the Microsoft Excel
202	software (https://www.microsoft.com/en-us/microsoft-365/excel) with an in-house built file.
203	It corresponded to the proportion of sequence reads that do not harbor the consensus

204 (majority) nucleotide. Genome sequences obtained in the present study were submitted to the

205 GISAID sequence database (https://www.gisaid.org/) [34] (see Supplementary Material:

206 Supplementary Table S1).

207 Generation of additional sequence reads

208 Sequencing of reverse-transcription-PCR-targeted regions: Extraction of the RNA 209 samples was carried out using the EZ1 Virus kit with the EZ1 Advanced XL instrument 210 (Qiagen) following the manufacturer's recommendations. PCR amplification of the 3 regions 211 was amplified in a 25 µL total volume using the SuperScript III One-Step RT-PCR Kit 212 (Invitrogen, Carlsbad, CA, USA), using primer concentrations of 200 nM per reaction. PCR 213 were performed with following conditions: 50°C for 25 min, 95°C for 2 min, then 40 cycles 214 including 15 s at 95°C, 45 s at 60°C, and 2 min at 68°C. Sequences of PCR primers are 215 provided in the Supplementary Material. Amplicons were sequenced with Nanopore 216 technology on a GridION instrument (Oxford Nanopore Technologies Ltd.), following 217 manufacturer's instructions. Fastq files were processed as described above. Continuous reads 218 overlapping signature mutations of distinct variants were filtered using SAMtools (v1.13; 219 https://github.com/samtools/) [40] combined with an in-house awk script. Reads were then 220 filtered according to variant-specific nucleotide patterns using SAMtools combined with an 221 in-house awk script. Groups of reads with same patterns of mutations were then visualized 222 using the IGV software (https://software.broadinstitute.org/software/igv/) [43]. 223 Metagenomic sequencing: Nucleic acid extraction was performed with the EZ1 Virus 224 kit with the EZ1 Advanced XL instrument (Qiagen) following the manufacturer's 225 recommendations, using 200  $\mu$ L of sample and eluting in 60  $\mu$ L of elution buffer. Reverse 226 transcription was performed with all 60 µL of this solution using the TaqMan Reverse 227 Transcription Reagent kit (Applied-Biosystems, Foster City, CA, USA), according to the 228 manufacturer's protocol under the following conditions: 10 min at 25°C, 30 min at 48°C, and

229 5 min at 95°C. Then, 300  $\mu$ L of obtained cDNA was transferred in a 1.5 mL Eppendorf

230 LoBind tube (Eppendorf, Le Pecq, France). Second DNA strand was synthesized by adding a 231 mix of 24 µL of Klenow Fragment DNA polymerase (New England Biolabs, Beverly, MA, 232 USA), 66 µL of nuclease-free water, 45 µL of NEB Buffer 2 (New England Biolabs), and 15 233  $\mu$ L of dNTPs working solution produced with 10  $\mu$ L of each dNTP at a 100 mM 234 concentration, and 60 µL of nuclease-free water (New England Biolabs). This mix was kept at 235 37°C for one hour. A purification step consisted in adding 450 µL of magnetic CleanNGS 236 beads for a 1:1 volume ratio (CleanNA, Waddinxveen, the Netherlands) then incubating for 5 237 min in a magnetic support, and washing with 1,000 µL of ethanol at 70%, before elution of 238 beads in 50  $\mu$ L of Tris EDTA 1X with centrifugation for 10 min at 300 rpm at room 239 temperature. Subsequently, DNA library was prepared with the DNA ligation sequencing kit 240 SQK-LSK109 (Oxford Nanopore Technologies Ltd.), and next-generation sequencing was performed with the Nanopore technology on a PromethION instrument (Oxford Nanopore 241 242 Technologies Ltd.). Each sample was sequenced on a different PromethION Flow cell R10.4

243 (Oxford Nanopore Technologies Ltd.).

### 244 Phylogenetic analysis on whole and partial genomes

Phylogenetic analyses were performed separately for the twelve genome sequences 245 246 and the twelve spike gene sequences obtained from the nasopharyngeal samples or the culture 247 supernatants. Sequences were aligned using MAFFT v.7 [44] with their 20 most similar hits 248 identified with the BLAST tool [45] among SARS-CoV-2 genomes from our database that 249 contains sequences obtained from clinical samples collected between February 2020 and 250 February 2022 [27,14]. Phylogeny reconstruction was performed using the IO-TREE software 251 with the GTR Model and 1,000 ultrafast bootstrap repetitions (http://www.iqtree.org) [46], 252 and trees were visualized with iTOL (Interactive Tree Of Life) (https://itol.embl.de/) [47] and

253 MEGA X (v10.2.6; https://www.megasoftware.net/) [47] softwares.

#### 254 Virus culture isolation

255

5 Culture isolation was performed on Vero E6 cells, as previously described [33].

256

257

#### 258 Acknowledgments

259 We are thankful to Ludivine Brechard, Claudia Andrieu, Raphael Tola, Jeremy

260 Delerce for their technical help; to Sophie Amrane and Justine Raclot for their help with the

261 clinical management; and to the medical biology laboratory Alphabio, hôpital Européen,

262 Marseille, France, for providing some results of SARS-CoV-2 qPCR testing.

#### 263 Author contributions

264 P.C., B.L.S., and D.R. conceived the project. E.B., P.C., J.-C.L., A.L., M.B., and P.L.

265 provided materials or performed analyses. E.B., P.C., J.-C.L., A.L., M.B., P.-E.F., B.L.S., and

266 D.R. analyzed the data. E.B., P.C., P.-E.F., B.L.S, and D.R. drafted the paper. All authors

267 participated in the discussion and interpretation of the results. All authors edited and

268 proofread the final manuscript. All authors have read and agreed to the published version of

the manuscript.

### 270 Funding

271 This work was supported by the French Government under the "Investments for the

272 Future" program managed by the National Agency for Research (ANR) (Méditerranée-

273 Infection 10-IAHU-03), by the Région Provence Alpes Côte d'Azur and European funding

274 FEDER PRIMMI (Fonds Européen de Développement Régional-Plateformes de Recherche et

d'Innovation Mutualisées Méditerranée Infection) (FEDER PA 0000320 PRIMMI), and by

the French Ministry of Higher Education, Research and Innovation (ministère de

277 l'Enseignement supérieur, de la Recherche et de l'Innovation) and the French Ministry of

278 Solidarity and Health (Ministère des Solidarités et de la Santé).

#### **Data availability**

The dataset generated and analyzed during the current study is available in the
GISAID sequence database (https://www.gisaid.org/) [34].

### **Conflicts of interest**

283	The authors have no conflicts of interest to declare relative to the present study. Didier
284	Raoult was a consultant for the Hitachi High-Technologies Corporation, Tokyo, Japan from
285	2018 to 2020. He is a scientific board member of the Eurofins company and a founder of
286	a microbial culture company (Culture Top). Funding sources had no role in the design and
287	con-duct of the study, the collection, management, analysis, and interpretation of the data, and
288	the preparation, review, or approval of the manuscript.
289	Ethics
290	This study has been approved by the ethics committee of University Hospital Institute
291	(IHU) Méditerranée Infection (No. 2022-008). Access to the patients' biological and registry
292	data issued from the hospital information system was approved by the data protection
293	committee of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the
294	European General Data Protection Regulation registry under number RGPD/APHM 2019-73.
295	
201	

298	8	REFERENCES
29	9	
30	0 1.	Xiao, Y.; Rouzine, IM.; Bianco S.; et al. RNA Recombination Enhances Adaptability
30	1	and Is Required for Virus Spread and Virulence. Cell Host Microbe. 2017, 22, 420. doi:
302	2	10.1016/j.chom.2017.08.006.
30.	3 2.	Bentley, K.; Evans, D.J. Mechanisms and consequences of positive-strand RNA virus
304	4	recombination. J Gen Virol. 2018, 99, 1345-1356. doi: 10.1099/jgv.0.001142.
30:	5 3.	Lai, MMC. Recombination in large RNA viruses: Coronaviruses. Semin Virol. 1996, 7,
30	б	381-388.
30′	7 4.	Zhang, Y.; Li, J.; Xiao, Y.; et al. Genotype shift in human coronavirus OC43 and
30	8	emergence of a novel genotype by natural recombination. J Infect. 2015, 70, 641-50.
30	9 5.	So, RTY.; Chu, DKW.; Miguel, E.; et al. Diversity of Dromedary Camel Coronavirus
31	0	HKU23 in African Camels Revealed Multiple Recombination Events among Closely
31	1	Related Betacoronaviruses of the Subgenus Embecovirus. J Virol. 2019, 93, e01236-19.
312	2	doi: 10.1128/JVI.01236-19.
31.	3 6.	Gribble, J.; Stevens, L.J.; Agostini, M.L.; et al. The coronavirus proofreading
314	4	exoribonuclease mediates extensive viral recombination. PLoS Pathog. 2021, 17,
31:	5	e1009226. doi: 10.1371/journal.ppat.1009226.
31	67.	Zhu, Z.; Meng, K.; Meng, G. Genomic recombination events may reveal the evolution
31′	7	of coronavirus and the origin of SARS-CoV-2. Sci Rep. 2020, 10, 21617. doi:
31	8	10.1038/s41598-020-78703-6.
31	98.	Jackson, B.; Boni, MF.; Bull, MJ.; et al. Generation and transmission of interlineage
32	0	recombinants in the SARS-CoV-2 pandemic. Cell. 2021, 184, 5179-5188.e8.
32	1 9.	Francisco, R.D.S. Jr.; Benites, L.F.; Lamarca, A.P.; et al. Pervasive transmission of
322	2	E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection

- 323 events by two different lineages in Rio Grande do Sul, Brazil. Virus Res. 2021, 296,
- 324 198345. doi: 10.1016/j.virusres.2021.198345.
- 325 10. Taghizadeh, P.; Salehi, S.; Heshmati, A.; et al. Study on SARS-CoV-2 strains in Iran
- 326 reveals potential contribution of co-infection with and recombination between different
- 327 strains to the emergence of new strains. Virology. 2021, 562, 63-73. doi:
- 328 10.1016/j.virol.2021.06.004.
- 329 11. Rockett, J.D.; Gall, M.; Sim, E.M.; et al. Co-infection with SARS-CoV-2 Omicron and
- 330 Delta Variants revealed by genomic surveillance. medRxiv 2022, 2022.02.13.22270755;
- doi: https://doi.org/10.1101/2022.02.13.22270755.
- 332 12. Musso, N.; Maugeri, J.G.; Bongiorno, D.; et al. SARS-CoV-2's high rate of genetic
- 333 mutation under immune selective pressure: from oropharyngeal B.1.1.7 to
- intrapulmonary B.1.533 in a post-vaccine patient. Int J Infect Dis. 2022, S1201-
- 335 9712(22)00123-0. doi: 10.1016/j.ijid.2022.02.044.
- 13. He, Y.; Ma, W.; Dang, S.; et al. Possible recombination between two variants of
- 337 concern in a COVID-19 patient. Emerg Microbes Infect. 2022, 11, 552-555. doi:
- 338 10.1080/22221751.2022.2032375.
- 339 14. Colson, P.; Fournier, P.E.; Delerce, J.; et al. Culture and identification of a
- 340 "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France medRxiv 2022,
- 341 2022.03.03.22271812; doi: https://doi.org/10.1101/2022.03.03.22271812
- 342 15. Yi, H. 2019 Novel Coronavirus Is Undergoing Active Recombination. Clin Infect Dis.
- 343 2020, 71, 884-887. doi: 10.1093/cid/ciaa219.
- 344 16. Yeh, T.Y.; Contreras, G.P. Emerging viral mutants in Australia suggest RNA
- recombination event in the SARS-CoV-2 genome. Med J Aust. 2020, 213, 44-44.e1.
- doi: 10.5694/mja2.50657. Epub 2020 Jun 7. PMID: 32506536; PMCID: PMC7300921.

- 17. Gallaher, W.R. A palindromic RNA sequence as a common breakpoint contributor to
- 348 copy-choice recombination in SARS-COV-2. Arch Virol. 2020, 165, 2341-2348. doi:
- 349 10.1007/s00705-020-04750-z.
- 350 18. VanInsberghe, D.; Neish, A.S.; Lowen, A.C.; Koelle, K. Recombinant SARS-CoV-2
- 351 genomes are currently circulating at low levels. bioRxiv. 2021 Mar
- 352 15:2020.08.05.238386. doi: 10.1101/2020.08.05.238386.
- 19. Haddad, D.; John, S.E.; Mohammad, A.; et al. SARS-CoV-2: Possible recombination
- and emergence of potentially more virulent strains. PLoS One. 2021, 16, e0251368.
- 355 20. Varabyou, A.; Pockrandt, C.; Salzberg, S.L.; Pertea, M. Rapid detection of inter-clade
- recombination in SARS-CoV-2 with Bolotie. Genetics. 2021, 218, iyab074. doi:
- 357 10.1093/genetics/iyab074.
- 358 21. Leary, S.; Gaudieri, S.; Parker, M.D.; et al. Generation of a novel SARS-CoV-2 sub-
- 359 genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous
- 360 recombination has potential to change SARS-CoV-2 at both protein and RNA level.
- 361 bioRxiv. 2021 Aug 6:2020.04.10.029454. doi: 10.1101/2020.04.10.029454. Update in:
- 362 Pathog Immun. 2021 Aug 20;6(2):27-49.
- 363 22. Lohrasbi-Nejad, A. Detection of homologous recombination events in SARS-CoV-2.
- 364 Biotechnol Lett. 2022, 17, 1–16. doi: 10.1007/s10529-021-03218-7.
- 365 23. Kreier, F. Deltacron: the story of the variant that wasn't. Nature. 2022, 602, 19.
- 366 24. Ignatieva, A.; Hein, J.; Jenkins, P.A. Ongoing Recombination in SARS-CoV-2
- 367 Revealed through Genealogical Reconstruction. Mol Biol Evol. 2022, 39, msac028. doi:
- 368 10.1093/molbev/msac028.
- 369 25. Sekizuka, T.; Itokawa, K.; Saito, M.; et al. Genome Recombination between Delta and
- 370 Alpha Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- 371 Jpn J Infect Dis. 2022 Feb 28. doi: 10.7883/yoken.JJID.2021.844.

- 372 26. Million, M.; Lagier, J.C.; Tissot-Dupont, H.; et al. Early combination therapy with
- 373 hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19
- 374 outpatients. Rev Cardiovasc Med. 2021, 22, 1063-1072. doi: 10.31083/j.rcm2203116.
- 27. Colson, P.; Fournier, PE.; Chaudet, H.; et al. Analysis of SARS-CoV-2 Variants From
- 376 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics.
- 377 Front Microbiol. 2022, 12, 786233. doi: 10.3389/fmicb.2021.786233.
- 378 28. Brouqui, P.; Colson, P.; Melenotte, C.; et al. COVID-19 re-infection. Eur J Clin Invest.
- 379 2021, 51, e13537. doi: 10.1111/eci.13537.
- 380 29. Drancourt, M.; Cortaredona, S.; Melenotte, C.; et al. SARS-CoV-2 Persistent Viral
- 381 Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment. Viruses.
- 382 2021, 13, 890. doi: 10.3390/v13050890.
- 383 30. Colson, P.; Devaux, C.A.; Lagier, J.C.; Gautret, P.; Raoult, D. A Possible Role of
- 384 Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-

385 CoV-2 Variants. J Clin Med. 2021, 10, 3276. doi: 10.3390/jcm10153276.

- 386 31. Rambaut, A.; Holmes, E.C.; O'Toole, A.; et al. A dynamic nomenclature proposal for
- 387 SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020, 5, 1403-
- 388 1407. doi: 10.1038/s41564-020-0770-5.
- 389 32. Aksamentov, I.; Roemer, C.; Hodcroft, E.B.; Neher, R.A. Nextclade: clade assignment,
  mutation calling and quality control for viral genomes. Zenodo 2021,
- 391 https://doi.org/10.5281/zenodo.5607694.
- 392 33. La Scola, B.; Le Bideau, M.; Andreani, J.; et al. Viral RNA load as determined by cell
- 393 culture as a management tool for discharge of SARS-CoV-2 patients from infectious

disease wards. Eur J Clin Microbiol Infect Dis. 2020, 39, 1059-1061.

- 395 34. Alm, E.; Broberg, EK.; Connor, T.; et al. Geographical and temporal distribution of
- 396 SARS-CoV-2 clades in the WHO European Region, January to June 2020. Euro
- 397 Surveill. 2020, 25, 2001410.

- 398 35. Fournier, P.E.; Colson, P.; Levasseur, A.; et al. Emergence and outcomes of the SARS-
- 399 CoV-2 'Marseille-4' variant. Int J Infect Dis. 2021, 106, 228-236.
- 400 36. Tengs, T.; Delwiche, C.F.; Monceyron Jonassen, C. A genetic element in the SARS-
- 401 CoV-2 genome is shared with multiple insect species. J Gen Virol. 2021, 102, 001551.
- 402 37. Le Glass, E.; Hoang, V.T.; Boschi, C.; et al. Incidence and Outcome of Coinfections
- 403 with SARS-CoV-2 and Rhinovirus. Viruses. 2021, 13, 2528.
- 404 38. Amona, I.; Medkour, H.; Akiana, J.; et al. Enteroviruses from Humans and Great Apes
- 405 in the Republic of Congo: Recombination within Enterovirus C Serotypes.
- 406 Microorganisms. 2020, 8, 1779.
- 407 39. Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018,
- 408 34, 3094-3100. doi:10.1093/bioinformatics/bty191
- 409 40. Hadfield, J.; Megill, C.; Bell, S.M.; Huddleston, J.; Potter, B.; Callender, C. Nextstrain:
- 410 real-time tracking of pathogen evolution. Bioinformatics. 2018, 34, 4121–4123.
- 411 41. Danecek, P.; Bonfield, J.K.; Liddle, J.; et al. Twelve years of SAMtools and BCFtools,
- 412 GigaScience 2021, 10, giab008, https://doi.org/10.1093/gigascience/giab008.
- 413 42. Garrison, E.; Marth, G. Haplotype-based variant detection from short-read sequencing.
  414 arXiv.org 2012, https://arxiv.org/abs/1207.3907.
- 415 43. Robinson, J.T.; Thorvaldsdottir, H.; Wenger, A.M.; Zehir, A.; Mesirov, J.P. Variant
- 416 Review with the Integrative Genomics Viewer (IGV). Cancer Research 2017, 77, 31-34.
- 417 44. Katoh, K.; Standley, D.M. MAFFT multiple sequence alignment software version 7:
- 418 improvements in performance and usability. Mol Biol Evol. 2013, 30, 772-780.
- 419 doi:10.1093/molbev/mst010
- 420 45. Altschul, S.F.; Gish, W.; Miller, W.; Myers, EW.; Lipman, D.J. Basic local alignment
- 421 search tool. J Mol Biol. 1990, 215, 403-10. doi: 10.1016/S0022-2836(05)80360-2.
- 422 46. Minh, B.Q.; Schmidt, H.A.; Chernomor, O.; et al. IQ-TREE 2: New Models and
- 423 Efficient Methods for Phylogenetic Inference in the Genomic Era [published correction

- 424 appears in Mol Biol Evol. 2020 Aug 1;37(8):2461]. Mol Biol Evol. 2020, 37, 1530-
- 425 1534. doi:10.1093/molbev/msaa015
- 426 47. Letunic, I.; Bork, P. Interactive tree of life (iTOL) v3: an online tool for the display and
- 427 annotation of phylogenetic and other trees. Nucleic Acids Res. 2016, 44, W242-W245.
- 428 doi:10.1093/nar/gkw290
- 429 48. Kumar, S.; Stecher, G.; Li, M.; Knyaz, C. Tamura K. MEGA X: Molecular
- 430 Evolutionary Genetics Analysis across Computing Platforms. Mol Biol Evol. 2018, 35,
- 431 1547-1549. doi: 10.1093/molbev/msy096.
- 432
- 433
- 434

435

# **FIGURE LEGEND**

436

437	Figure 1. Schematic representation of the structure of the SARS-CoV-2 genomes
438	obtained from the nasopharyngeal samples and from the culture supernatants and of the
439	recombination events over time, in reference to parental genomes of the B.1.160 and
440	Alpha variants.
441	a. Genome map and annotation. b. Genome structure and mutations. Blue color of rectangles
442	indicates sequences from a B.1.160 variant; yellow color indicates sequences from an Alpha
443	variant; green color indicates co-detection of sequences from a B.1.160 variant and from an
444	Alpha variant; grey color indicates sequences from indeterminate origin. Signature mutations
445	from the B.1.160 and Alpha variants are indicated by a blue background and a yellow
446	background, respectively. Signature mutations that are absent are indicated by a red font.
447	$\Delta$ 21765: -6 nucleotides; $\Delta$ 21991: -3 nucleotides. Nsp, nonstructural protein; ORF, open
448	reading frame.
449	
450	Figure 2. Majority nucleotides (a) and nucleotide diversity (b) for sequences obtained
451	from the respiratory samples and the culture supernatant at nucleotide positions of the
452	SARS-CoV-2 genome that harbor signature mutations of the B.1.160 or Alpha variants.
453	Nucleotide positions are in reference to the genome of the Wuhan-Hu-1 isolate GenBank
454	accession no. NC_045512.2.
455	a: B.1.160 nucleotides are indicated by a blue background; Alpha nucleotides are indicated by
456	a yellow background. Del, nucleotide deletion
457	b: Nucleotide diversity is the proportion of sequence reads that do not harbor the consensus
458	(majority) nucleotide.
459	
460	Figure 3. Phylogenetic analyses based on SARS-CoV-2 genomes (a) and spike gene

- 461 sequences (b).
- 462 Sequences obtained from the case-patient are indicated by a grey background, and those
- 463 obtained from cultures are underlined. Other sequences from our SARS-CoV-2 sequence
- 464 database are indicated by a blue font when classified as of the B.1.160 variant, and by a
- 465 yellow font when classified as of the Alpha variant. Sequences are labeled with their GISAID
- 466 (https://www.gisaid.org/) [34] identifiers. Trees are rooted with the genome of the Wuhan-
- 467 Hu-1 isolate GenBank accession no. NC\_045512.2.

468

#### 

# TABLE

#### 

Table 1. Genome sequences obtained from the sequential nasopharyngeal samples of the casepatient 

#### 

GISAID identifier	Sampling time post- diagnosis (months)	Next-generation sequencing technology, instrument
EPI_ISL_6332079	M0	Illumina, NovaSeq
EPI_ISL_10816743	Month 8	Illumina, NovaSeq
EPI_ISL_11030507	Month 9	Illumina, NovaSeq
EPI_ISL_10816731	Month 10	Illumina, NovaSeq
EPI_ISL_10816742	Month 11	Nanopore, GridION
EPI_ISL_10816744	Month 13	Illumina, NovaSeq
EPI_ISL_10816733	Month 14	Illumina, NovaSeq

#### 

#### **Table 2.** Genome sequences obtained from the culture supernatants

GISAID identifier	Sampling date of the nasopharyngeal sample	Time to cytopathic effect (days)	Next-generation sequencing technology,
			instrument
EPI_ISL_10816730	Month 8	8	Illumina, NovaSeq
EPI_ISL_10816732	Month 9	4	Illumina, NovaSeq
EPI_ISL_10816734	Month 11	4	Illumina, NovaSeq
EPI_ISL_10816735	Month 14	5	Illumina, NovaSeq
EPI_ISL_10816738	Month 14	7	Illumina, NovaSeq



#### RNA-dependent RNA polymerase Envelope glycoprotein ORF8 ORF7b a. Genome map and annotation nsp7 nsp9 NTPase/helicase domain ORF9b ORF7a 3C-like proteinase nsp6 nsp8 nsp10 nsp1 nsp15 ORF6 ORF14 Spike glycoprotein ORF3a nsp16 ΪĒ ORF10 Predicted phosphoesterase RdRp Hel nsp14 PLpro S nsp2 nsp4 3CL 5,000 10,000 15,000 20,000 25.000 29,903 membrane glycoprotein Nucleocapsid phosphprotein **b.** Genome structure and mutations Parental B.1.160 (Marseille-4) variant genome SARS-CoV-2 diagnosis Month 8 Nasopharyngeal samples C3267U C4543U C28977U G29399A C18877U G17019U Month 9 U26876C C27972U C18877U Δ21765 Month 10 C26735U Month 11 C913U G24914C G25563U Month 13 U26876C Month 14



C18877U

C3267U

Fig. 2			
			Г

			а.					Mai	ority n	ucleo	tides					b	<b>D.</b> Nucleotide diversity (								
					N	asopha	iryngea	ıl samp	les			Cultur	e super	matants	s				Nasoph	aryngeal	samples				
Nucleotide positions	Wuhan-Hu-1 isolate genome	Signature mutations in B.1.160/Marseille-4 genomes	Signature mutations in Alpha genomes	SARS-CoV-2 diagnosis	Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	Month 9	Month 11	Month 14	Month 14		SARS-CoV-2 diagnosis	Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	
913	С	-	U	-	-	-	U	U	U	U	-	-	U	U	U		0,0	33,9	26,8	35,9	10,0	0,1	0,1	9,0	
3267	C	-	U	-	-	-	U	U	U	-	-	-	U	-	-		0.0	28.8	23.7	39.3	6.8	0.0	0.0	2.4	
4543	С	U	-	U	U	U	U	U	U	U	U	U	U	U	U		0,1	0,0	0,0	0,0	7,8	0,0	0,1	0,3	
5629	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U		2.8	0.5	1.6	0.2	11.4	0.6	0.0	0.8	
5986	C	-	U	-	-	-	-	-	-	-	-	-	U	-	-		0.0	0.0	0.0	0.0	10.3	0.0	0.0	0.0	
9526	Ĝ	U	-	U	U	U	U	U	U	U	U	U	Ū	U	U		0.1	0,0	0.0	0.0	4.6	0.0	0.8	12	
11497	Č	Ŭ	-	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ	Ŭ		0.4	0,0	0.0	0.3	2.5	0.4	0.0	0.1	
13993	G	Ŭ		Ū	Ŭ	Ū	Ū	Ŭ	Ŭ	Ŭ	U U	Ū	Ŭ	Ŭ	Ŭ		0.1	0.1	0,0	0.1	5.4	0.1	0,0	0.0	
15766	G	U U	_	U U	Ŭ	U U	Ŭ	U U	U U	Ŭ U	U U	U U	U U	Ŭ U	Ŭ U		0,1	0.3	0,0	0.1	9.2	0,1	0,0	0,0	
16889	Δ	G	-	G	G	G	G	G	c	G	G	G	G	G	G		0,1	0,5	0,0	0.0	77	0,0	0,0	0,0	
17010		U U	-	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U	U U		0,1	0,0	0,0	0,0	15.6	0,0	0,2	0,0	
18877	C	U	-		U	U U	U	U	U U	U	U	U	U U	U	U		0,0	47.0	0,0	0,0	6.8	0,0	0,0	27	
21765		U	- Del	U	-	U	U	Del	Del	- Dal	U	U	Del	- Del	- Dal		0,0	47,0	11.0	28.2	0,0	22.6	22.0	2,7	
21705		-	Del	-	-	-	-	Del	Del	Del	-	-	Del	Del	Del		0,1	14,7	11,0	38,3	39,2	22,0	22,9	2,1	
21760	A	-	Del	-	-	-	-	Del	Del	Der	-	-	Del	Del	Del		0,0	16,2	11,8	44,0	10,9	1,0	1,1	2,2	
21767	C	-	Del	-	-	-	-	Del	Del	Del	-	-	Del	Del	Del		0,1	15,4	11,1	42,8	19,6	0,0	0,0	2,1	
21768	A	-	Del	-	-	-	-	Del	Del	Del	-	-	Del	Del	Del		0,0	15,4	11,2	43,1	10,4	0,0	0,0	2,1	
21769	U	-	Del	-	-	-	-	Del	Del	Del	-	-	Del	Del	Del		0,0	15,6	11,5	43,7	13,7	0,2	0,2	2,1	
21770	G	-	Del	-	-	-	-	Del	Del	Del	-	-	Del	Del	Del		0,1	18,2	15,2	47,6	9,6	5,6	5,6	3,6	
21991	U	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del		0,0	20,3	17,3	18,6	22,1	1,3	4,3	0,1	
21992	U	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del		0,1	20,4	16,9	18,1	20,3	1,3	5,6	0,1	
21993	Α	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del		0,1	20,6	16,7	17,7	17,8	3,7	18,9	0,1	
22992	G	Α	-	Α	Α		-	-	-	-	Α	Α	-	-	-		0,3	33,3		20,6	4,8	0,0	0,0	5,5	
23063	A	-	U	-	-	-	U	U	U	U	-	-	U	U	U		0,0	50,0	33,3	27,1	12,4	0,0	0,0	6,7	
23271	C	-	Α	-	-	-	Α	Α	Α	Α	-	-	Α	Α	Α		0,2	15,7	20,0	44,2	4,2	0,0	0,1	5,1	
23604	C	-	Α	-	-	-	Α	Α	Α	Α	Α	-	Α	Α	Α		0,1	24,8	25,6	37,8	6,0	0,0	0,1	32,7	
23709	C	-	U	-	-	-	U	U	U	U	-	-	U	U	U		0,1	27,5	28,1	37,8	7,8	0,0	0,1	3,5	
24506	U	-	G	-	-	-	G	G	G	G	-	-	G	G	G		0,0	31,2	25,0	31,9	17,7	0,0	0,1	3,2	
24914	G	-	С	-	-	-	С	С	С	С	-	-	С	С	С		0,0	11,6	24,7	43,9	18,7	0,0	0,1	4,4	
25563	G	U	-	U	U	U	-	U	-	-	U	U	U	-	-		0,0	46,2	40,2	20,4	27,4	0,0	0,0	5,6	
25710	C	U	-	U	-	U	-	U	-	-	U	U	U	-	-		0,1	42,2	34,4	17,6	26,0	0,0	0,1	7,4	
26735	C	U	-	U	-	-	-	-	-	-	U	U	U	U	-		0,0	37,9	43,5	9,1	8,6	0,0	19,6	17,0	
26876	U	С	-	С	-	-	-	С	-	-	С	С	С	С	-		0,0	39,2	46,4	12,6	37,2	0,0	22,5	14,7	
28975	G	С	-	С	-	С	С	С	С	С	С	С	С	С	С		0,4	32,8	0,0	0,0	16,6	0,0	5,5	7,3	
28977	C	-	U	-	U	-	-	-	-	-	-	-	-	-	-		0,0	45,1	2,5	0,0	2,8	0,7	0,0	7,3	
29399	G	Α	-	Α	Α	Α	Α	Α	Α	Α	Α	Α	Α	Α	Α		0,0	0,1	0,0	0,0	9,3	0,0	0,0	0,0	
																<b></b>									
																Mean	0,2	20,1	14,7	19,8	13,2	1,1	3,1	4,3	

Standard deviation Median

0,0	33,9	26,8	35,9	10,0	0,1	0,1	9,0	0,1	0,1	0,1	0,3
0,0	28,8	23,7	39,3	6,8	0,0	0,0	2,4	0,1	0,2	0,4	0,1
0,1	0,0	0,0	0,0	7,8	0,0	0,1	0,3	0,2	0,2	0,8	0,1
2,8	0,5	1,6	0,2	11,4	0,6	0,0	0,8	1,9	0,9	5,3	1,5
0,0	0,0	0,0	0,0	10,3	0,0	0,0	0,0	0,0	18,4	0,0	0,1
0,1	0,0	0,0	0,0	4,6	0,0	0,8	1,2	0,2	0,2	0,0	0,3
0,4	0,0	0,0	0,3	2,5	0,4	0,0	0,1	0,3	0,2	0,1	0,2
0,1	0,1	0,0	0,1	5,4	0,1	0,0	0,0	0,1	0,0	0,3	0,1
0,1	0,3	0,0	0,1	9,2	0,0	0,0	0,0	0,1	0,0	0,1	0,1
0,1	0,0	0,0	0,0	7,7	0,0	0,2	0,0	0,1	0,0	0,3	0,1
0,0	0,0	0,0	0,0	15,6	0,0	0,0	0,3	0,2	0,4	0,1	0,1
0,0	47,0	0,0	0,0	6,8	0,0	0,1	2,7	0,2	0,0	0,2	0,1
0,1	14,7	11,0	38,3	39,2	22,6	22,9	2,1	0,0	21,8	23,7	21,2
0,0	16,2	11,8	44,0	10,9	1,6	1,1	2,2	0,0	1,2	1,6	1,0
0,1	15,4	11,1	42,8	19,6	0,0	0,0	2,1	0,0	0,0	0,1	0,0
0,0	15,4	11,2	43,1	10,4	0,0	0,0	2,1	0,0	0,0	0,1	0,1
0,0	15,6	11,5	43,7	13,7	0,2	0,2	2,1	0,1	0,2	0,5	0,5
0,1	18,2	15,2	47,6	9,6	5,6	5,6	3,6	0,0	7,2	6,4	6,5
0,0	20,3	17,3	18,6	22,1	1,3	4,3	0,1	2,1	2,5	0,7	1,4
0,1	20,4	16,9	18,1	20,3	1,3	5,6	0,1	2,1	2,5	2,0	2,1
0,1	20,6	16,7	17,7	17,8	3,7	18,9	0,1	11,5	7,4	10,7	12,6
0,3	33,3		20,6	4,8	0,0	0,0	5,5	0,1	0,0	0,2	0,3
0,0	50,0	33,3	27,1	12,4	0,0	0,0	6,7	0,1	0,0	0,4	0,4
0,2	15,7	20,0	44,2	4,2	0,0	0,1	5,1	0,0	0,3	0,2	0,2
0,1	24,8	25,6	37,8	6,0	0,0	0,1	32,7	0,0	0,9	0,6	0,2
0,1	27,5	28,1	37,8	7,8	0,0	0,1	3,5	0,1	0,1	0,1	0,1
0,0	31,2	25,0	31,9	17,7	0,0	0,1	3,2	0,1	0,0	0,1	0,1
0,0	11,6	24,7	43,9	18,7	0,0	0,1	4,4	0,0	0,0	0,2	0,1
0,0	46,2	40,2	20,4	27,4	0,0	0,0	5,6	0,1	0,3	0,2	0,1
0,1	42,2	34,4	17,6	26,0	0,0	0,1	7,4	0,1	0,0	0,3	0,0
0,0	37,9	43,5	9,1	8,6	0,0	19,6	17,0	0,0	0,1	0,3	0,2
0,0	39,2	46,4	12,6	37,2	0,0	22,5	14,7	0,2	0,2	0,2	0,2
0,4	32,8	0,0	0,0	16,6	0,0	5,5	7,3	0,0	0,1	0,1	0,3
0,0	45,1	2,5	0,0	2,8	0,7	0,0	7,3	0,0	0,0	0,2	0,1
0,0	0,1	0,0	0,0	9,3	0,0	0,0	0,0	0,0	0,1	0,1	0,5
0.2	20.1	147	10.0	12.2	11	2.1	4.2	0.0	1.0	1.(	1.5
0,2	20,1	14,7	19,8	13,2	1,1	3,1	4,3	0,6	1,9	1,6	1,5
0,5	16,4	14,3	18,2	8,9	3,9	6,8	6,4	2,0	4,9	4,4	4,1
0,1	18,2	11,6	18,1	10,3	0,0	0,1	2,2	0,1	0,2	0,2	0,2

Month 9

Culture supernatants

Month 11

Month 14

Month 14





# 1

3

## SUPPLEMENTARY MATERIAL

#### 2 **Full-length title:**

Sequential appearance and isolation of a SARS-CoV-2 recombinant between two major

4 SARS-CoV-2 variants in a chronically infected immunocompromised patient

5

### 6 SUPPLEMENTARY METHODS

At our institute, SARS-CoV-2 real-time reverse-transcription-PCR (qPCR) was
performed on nasopharyngeal samples collected from patients tested by real-time reverse-

9 transcription-PCR (qPCR) using the BGI real-time fluorescent RT-PCR assay (BGI

10 Genomics, Shanghai Fosun Long March Medical Science Co., Ltd., Shenzhen, China) or the

11 NeuMoDx SARS-CoV-2 assay (NeuMoDx Molecular, Ann Arbor, Michigan). Outside our

12 institute (medical biology laboratory Alphabio, hôpital Européen, France), SARS-CoV-2

13 qPCR was performed using the BD MAX System (Becton Dickinson, Sparks, MD, USA).

14

### 15 SUPPLEMENTARY RESULTS

#### 16 Virological follow-up by SARS-CoV-2 real-time reverse-transcription-PCR (qPCR)

17SARS-CoV-2 qPCR performed on nasopharyngeal samples was positive between18summer 2020 (at time of SARS-CoV-2 diagnosis) and Month 4 post-diagnosis, then negative19once at Month 5 but positive again on the next sample tested in Month 7. Between Month 820and Month 11, qPCR remained almost always positive being only transiently negative for  $\leq$ 321days. Then qPCR was consistently positive when performed between Month 13 and Month 1422post-diagnosis.

23 Nucleotide diversity at positions harboring signature mutations of the B.1.160 or Alpha

24 variants

25 Regarding the SARS-CoV-2 genomes obtained from the respiratory samples, which

were obtained with the Illumina technology except for the sample collected at Month 11 post-26 27 SARS-CoV-2 diagnosis for which the genome was obtained with the Nanopore technology, 28 nucleotide di-versity at the 35 positions harboring signature mutations of the B.1.160 or Alpha 29 variants differed according to the time of sample collection. It was low at time of diagnosis in 30 2020, with a mean ( $\pm$ standard deviation) value of 0.2 $\pm$ 0.5%, increased to reach high values at 31 Month 8 (20.1±16.4%), at Month 9 (14.7±14.3%), at Month 10 (19.8±18.2%), and at Month 32 11 (13.2 $\pm$ 8.9%), then decreased to low values again at Month 13 (1.1 $\pm$ 3.9%) and at Month 14 33  $(3.1\pm6.8\%)$  (Figure 2 of the main text). The low nucleotide diversity observed for genomes 34 obtained at Month 13 and at Month 14 indicated that the mosaicism consisting in the presence 35 of signature mutations of the two variants was not explained by a co-infection by these two 36 variants or by a contamination of the samples prior or during the next-generation sequencing 37 procedure. 38 Regarding the genomes obtained from the culture supernatants, which were all ob-tained with 39 the Illumina technology, nucleotide diversity at positions harboring signature mutations of the 40 B.1.160 or Alpha variants was low, indicating that these genomes, including those 41 recombinants, were generated from a single viral isolate. Indeed, mean nucleotide diversity

42 ranged between  $0.6\pm 2.0\%$  and  $4.3\pm 6.4\%$  (Figure 2 of the main text). The viral genomes

43 obtained from the culture of the respiratory samples collected at Month 14 were highly similar

44 to the viral genome obtained directly from the respiratory sample collected at Month 14.

45 Generation of additional sequence reads

Sequencing of reverse-transcription-PCR-targeted regions: We attempted to generate
sequence reads that are hybrids of the B.1.160 and Alpha variants from the respiratory sample
collected at Month 11 by PCR amplification of the regions overlapping re-combination sites
then next-generation sequencing with the Oxford Nanopore Technol-ogy (ONT) on a
GridION instrument (Oxford Nanopore Technologies Ltd., Oxford, United Kingdom).

51	Amplicons corresponding to positions 3,100-4,570 (in reference to the genome of the Wuhan-
52	Hu-1 isolate GenBank accession no. NC_045512.2) were amplified using the following
53	primers (in 5'-3' orientation): Forward: TTCAACCTGAAGAA-GAGCAA; reverse:
54	TGGCATTGTAACAAGAGTTT. Amplicons corresponding to posi-tions 24,813-29,074
55	were amplified using the following primers: Forward: ATGGAAAAGCACACTTTCCT;
56	reverse: GCTTTAGTGGCAGTACGTTT. For the am-plicons corresponding to positions
57	3,100-4,570, 87% of the reads were hybrids harboring both Alpha (C3267U) and B.1.160
58	(C4543U) signature mutations. For the amplicon cor-responding to positions 24,813-29,074,
59	70% of the reads were hybrids harboring Alpha (G24914C) and B.1.160 (G25563U,
60	C25710U, C26735U, U26876C and G28975C) mutations, and 24% were hybrids harboring
61	Alpha mutation G24914C and B.1.160 mutation G28975C.
62	Metagenomic sequencing: Next-generation sequencing was also carried out using a
63	metagenomic approach with the Nanopore technology on a GridION instrument (Oxford
64	Nanopore Technologies Ltd.) to attempt obtaining long sequence reads and detect addi-tional
65	reads that are hybrids of the B.1.160 and Alpha variants. For the first recombination site, four
66	reads with a length ranging between 1,855-11,979 nucleotides were obtained, which harbored
67	signature mutations of the Alpha (C3267U) and B.1.160 (C4543U) variants. For the third
68	recombination site, four reads with a length comprised between 1,486-8,143 nucleotides were
69	obtained that harbored signature mutations of the Alpha (G24914C) and B.1.160 (C25563U)
70	variants.
71	Viral culture

Cytopathic effects were observed between 4 and 8 days after the inoculation of the
nasopharyngeal samples on Vero E6 cells as previously described [1] (Table 2 of the main
text).

75 Phylogenetic analyses based on SARS-CoV-2 genomes and spike gene sequences

76 Phylogeny reconstructions were performed based on viral genomes or spike genes, 77 which included sequences obtained directly from the nasopharyngeal samples and from the 78 cultures, and their best BLAST hits from the IHU Méditerranée Infection sequence database 79 that were classified as B.1.160 or Alpha variants [2]. The genome obtained from the 80 nasopharyngeal sample collected in 2020 at time of SARS-CoV-2 diagnosis was clustered 81 with genomes of the B.1.160 variant, apart from the other genomes obtained from the case-82 patient (Figure 3a of the main text). Other genomes obtained from the nasopharyngeal 83 samples collected since Month 8 and those obtained from cultures of the nasopharyngeal 84 samples collected since Month 8 were also clustered with genomes of the B.1.160 variant, but 85 they were clustered together, apart from the other genomes. The Alpha variant genomes were 86 clustered apart from all other genomes. Spike gene phylogeny showed the clusterisation with 87 sequences of the B.1.160 variant of the sequences obtained from the case-patient either 88 directly or post-culture from samples collected between SARS-CoV-2 diagnosis and Month 9 89 post-diagnosis (Figure 3b of the main text). In contrast, sequences obtained from the case-90 patient either directly or post-culture from samples collected since Month 10 post-diagnosis 91 were clustered with Alpha variant sequences.

92

#### 93 SUPPLEMENTARY FIGURES

94 Supplementary Figure S1. Majority nucleotides and nucleotide diversity for sequences

95 obtained from the respiratory samples and the culture supernatant at nucleotide

96 positions of the SARS-CoV-2 genome that harbor signature mutations of the B.1.160 or

97 Alpha variants and at any other positions that harbor mutations.

98 Nucleotide positions are in reference to the genome of the Wuhan-Hu-1 isolate GenBank

99 accession no. NC\_045512.2. B.1.160 nucleotides are indicated by a blue background; Alpha

100 nucleotides are indicated by a yellow background. Del, nucleotide deletion. Nucleotide

- diversity is the proportion of sequence reads that do not harbor the consensus (majority)
- nucleotide.

	<u>و</u>	s	ø	Majority nucleotides											Nucleotide diversity (%)												
~	E E	in Ome	VIpha	<u> </u>	Na	sopha	ryngea	al sam	ples		(	Culture	e supe	rnatar	its		N	asopha	ryngea	l samp	les			Cultur	e super	natant	5
Nucleotide position	Wuhan-Hu-1 isolate gei	Signature mutations B.1.160/Marseille-4 gend	Signature mutations in A genomes	SARS-CoV-2 diagnosis	Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	Month 9	Month 11	Month 14	December 2nd, 2021	SARS-CoV-2 diagnosis	Month 8	Month 9	Month 10	Month 11	Month 13	Month 14	Month 8	Month 9	Month 11	Month 14	Month 14
7 241	G C	Ū	Ū	- U	- U	- U	U U	Ū	Ū	Ū	- U	Ū	- U	Ū	Ū	0,0 0,0	0,0 0,0	0,0 0,0	0,0 0,1	0,0 10,6	0,0 0,0	0,0 0,1	16,7 0,0	0,0 0,1	0,0 0,0	0,0 0,0	/ 0,4
629	C	-	-	-	U	U	U	U	U	U	-	-	U	U	U	0,2	45,5	13,2	25,1	28,4	0,1	1,0	6,4	0,1	0,2	0,1	0,3
696 913		-	Ū	-	-	-	U	U	UU	U	-	-	U	U	UU	0,0	37,5 33.9	29,6 26.8	32,0 35.9	4,5	0,2	0,1 0,1	4,9	0,0	0,1	0,5	0,2 0.3
981	C	-	-	-	-	-	-	-	-	U	-	-	-	-	-	0,0	0,0	0,1	0,0	4,0	0,0	14,0	0,0	0,2	0,1	0,4	0,4
1192 1677	A	-		-	-	-	-	-	G	-	-	-	-	- C	-	0,2	0,0	0,1	0,2	2,6	33,3	0,0	0,0	0,0	0,1	0,1	0,1
1683	Ū	-	-	-	-	-	-	-	-	c	2	-	-	-	c	0,0	0,0	0,0 0,0	0,0	1,4	0,0	18,5	0,1	0,1	0,1	0,5	0,0
1895	G	-	-	-	-	-	-	-	A	-	-	-	-	-	-	0,5	0,0	0,0	0,0	6,4	0,0	0,0	0,0	0,0	0,5	0,0	0,3
2509	C	-	1	-	-	-	-	-	-	-	-	-	-	Ū	-	0,1	0,0	0,0 0,0	0,0 0,0	3,4	0,0	7,4	0,1	0,2	0,0	0,2	0,3
2594	C	-	-	-	-	-	-	-	-	U	-	-	-	U	U	0,0	0,0	0,0	0,0	2,2	0,0	0,0	0,1	0,0	0,0	0,1	0,2
2706		Ū	Ū	Ū	UUU	UU	- U	Ū	Ū	UU		UU	Ū	UU	UUU	0,1	43,6	25,0	28,1 0.0	5,4 20.8	0,0 0.0	0,1 0.1	4,3	0,1 0.1	0,0 0.0	0,2 0,4	0,0
3193	Α	-	-	-	-	-	G	Ğ	G	-	-	-	G	-	-	0,3	0,0	25,5	33,4	21,2	0,9	0,0	0,0	0,0	2,6	0,0	0,6
3224	A	-	-	-	-	-	-	-	G	-	-	-	-	-	-	0,0	0,0	0,0	0,0	6,3	0,1	0,1	0,0	0,0	0,0	0,0	0,0
3340	G	-	-	-	-	-	-	-	-	-	-	-	-	- U	-	0,0	16,8	0,0	0,0	2,3	0,0	12,7	0,1	0,1	0,2	0,4	0,1
3393	C	-	-	-	-	U	-	-	-	-	U	U	-	-	-	0,3	28,7	43,4	20,8	4,6	0,0	0,2	2,4	0,0	0,0	0,0	0,1
4543	A	-		-	G	G	-	-	-	-	G	G	-	-	-	0,1	0,0	12,5	37,1	2,9	0,0 0,0	0,1	0,3	0,2 0,1	0,2	0,8	0,1
4878	C	-	-	-	U	U	U	U	U	U	U	U	U	U	U	0,0	0,0	0,0	0,0	6,6	0,0	0,2	0,1	0,1	0,1	0,2	0,2
4893	C	-	-	-	-	-	U	U	U	U	-	-	U	U	U	0,1	0,0	27,3	43,3	5,2	0,6	0,0	0,1	0,0	0,2	0,1	0,2
5278	U	-	-	-	-	-	-	-	-	-	-	-	-	c	-	0,9	0,0	0,0	0,0	2,1	0,0	14,6	0,0	0,0	0,0	8,0	0,1
5629	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U	2,8	0,5	1,6	0,2	11,4	0,6	0,0	0,8	1,9	0,9	5,3	1,5
5986	C	-	Ū	-	-	-	-	-	-	-	-	-	Ū	-	-	0,1	0,1	0,0 0,0	0,0 0,0	1,6	0,0 0,0	0,1	0,1	0,0	18,4	0,2	0,1
6629	C	-	-	-	-	U	-	-	-	-	-	U	-	-	-	0,0	0,0	37,7	15,6	5,6	0,0	0,0	0,0	0,3	0,3	0,1	0,1
6633 7113		-	1	-	U -	U -	U	U	U	U U	U	U	U -	U -	UUU	0,0	0,2	0,0	0,0 0.0	11,0	0,1 0.0	0,0	0,0	0,1 0.0	0,3	0,1 0.3	0,2
7185	Ū	-	-	-	С	С	С	С	С	č	С	С	С	С	C	0,1	0,0	0,0	0,0	10,9	0,0	0,0	0,1	0,0	0,0	0,4	0,1
7279	C	-	-	-	-	-	-	-	-	U	-	-	-	-	-	0,1	0,0	0,0	2,7	2,5	0,0	31,3	0,2	0,3	0,5	0,3	0,5
8770	c	-		-	Ū	-	-	-	-	-	-	-	-	-	-	0,0	47,2	0,0	0,0	10,6	0,2	0,2	3,1	0,0	0,0	0,2	0,0
8950	C	-	-	-	-	-	-	-	-	-	-	U	-	-	-	0,1	0,0	48,1	14,9	1,6	0,1	0,1	0,2	0,1	0,1	0,2	0,1
9042 9120		-	1	-	UU	UU	UU	UU	UU	UU		UU	UU	UU	UU	0,0	0,1	0,1	0,2	17,7 8.6	0,0 0,0	0,1 0,3	0,1	0,5	0,1	0,1 0,2	0,3
9501	C	-	-	-	U	-	U	U	U	U	U	U	U	U	U	0,0	0,0	/	0,0	9,1	0,0	0,0	0,6	2,6	0,4	0,5	2,2
9526 9626	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U	0,1	0,0	0,0	0,0 0.0	4,6	0,0 0.0	0,8	1,2	0,2 0 1	0,2	0,0	0,3
9783	G	-	1	-	-	-	-	c	-	-	2	-	-	-	-	0,0	0,0		0,0	35,0	0,0	0,0	0,0	0,1	0,0	0,0	0,3
9792	A	-	-	-	-	С	-	-	-	-	-	-	-	-	-	0,0	16,7	0,0	0,0	2,2	0,0	0,0	1,2	0,0	0,0	0,0	0,0
9972	A	-	-	-	-	-	-	-	-	G	-	-	-	-	-	0,1	0,0	0,0 0,0	0,0	6,1 5,7	0,0	2,9	0,0	0,1	0,2	0,7	0,6
11083	G	-	-	-	-	-	-	-	-	-	U	-	-	-	-	1,0	1,1	0,0	0,0	2,2	0,0	0,7	27,1	0,1	0,1	0,7	0,5
11208		-	-	-	U	U	U	U	U	UU	U	U	U	U	UU	0,0	0,0	0,2	0,1	4,6	0,2	0,0 19.2	0,2	0,1 0.0	0,0	0,2 0,1	0,1
11497	C	U	-	U	U	U	U	U	U	U	U	U	U	U	U	0,4	0,0	0,0	0,3	2,5	0,4	0,0	0,1	0,3	0,2	0,1	0,2
12459	C	-	-	-	-	U	-	-	-	-	-	U	-	-	-	0,4	0,0	45,8	20,6	3,1	0,0	0,1	0,3	0,1	0,4	0,2	0,3
13506	c	-	-	-	Ū	U	Ū	Ū	Ū	Ū	Ū	U	Ū	Ū	Ū	0,0	0,2	0,0	0,0	13,9	0,0	0,0	0,1	0,1	0,0	0,1	0,1
13517	C	-	-	-	-	-	-	-	U	-	-	-	-	-	-	0,3	0,0	0,0	0,0	3,6	16,7	0,1	0,4	0,1	0,6	0,1	0,2
13860	G	-		-	-	-	-	-	-	-	-	-	-	-	Ū	0,2	0,1	24,2	35,4 0.0	3,9 4.3	0,1	0,1	0,1	0,2	0,0	0,1 0.1	0,2 3,0
13993	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U	0,1	0,1	0,0	0,1	5,4	0,1	0,0	0,0	0,1	0,0	0,3	0,1
14408	G		U	U	U	U	U	U	U	U	U	U	U	U	Ŭ U	0,1	0,1 0.3	0,0 0.0	0,1 0.1	11,0 9.2	0,1	0,4	0,1	0,3 0.1	0,0 0.0	0,3 0.1	0,2
16128	A	-	-	-	-	-	-	-	-	-	-	-	-	G	-	0,2	0,0	0,1	0,1	2,3	0,0	13,9	0,0	0,0	0,0	12,1	0,0
16675	C	-	-	-	U	U	U	U	U	U	U	U	U	U	U	0,1	0,2	0,0	0,2	13,2	0,1	0,0	0,1	0,7	0,5	0,2	0,1
16889	A	G	1	G	G	G	G	G	G	G	G	G	G	G	G	0,1	0,0	0,0	0,2	7,7	0,4	0,0	0,0	0,9 0,1	0,0	0,0	0,0
17019	G	U	-	U	U	U	U	U	U	U	U	U	U	U	U	0,0	0,0	0,0	0,0	15,6	0,0	0,0	0,3	0,2	0,4	0,1	0,1
17122	G	-	1	-	-	2	- U	Ū	Ū	U -	-	-	- U	2	U	0,1	0,0	0,0 18-9	0,0 43.4	11,9 18.4	0,1 0,1	16,0	0,0 0,1	0,1 0.0	0,1 0,1	0,1 0,2	0,1 0,2
17251	c	-	-	-	U	U	U	U	Ŭ	U	U	Ū	U	Ū	U	0,0	0,3	0,1	0,1	11,1	0,2	0,1	0,2	0,1	0,1	0,5	0,5

#### 105 Supplementary Figure S2 (continued)

	_																										
	6	s					M	ajorit	ty nuc	leotic	les									Nucle	otide c	liversi	ty (%)				
		- ñ	hd		Nas	sophar	yngea	l sam	ples		(	Julture	e supe	rnatar	its		N	asopha	ryngea	l samp	les			Culture	e super	natants	;
Suc	Gen	is ir	IAI																								
iti	E	ion es	s II.	SIS.											51	SIS											
bos	lai	tat e-4	ion	0ug											20	guo											
le	is.	eill	orr	dia	~	6	10	Ξ	13	4	~	6	Ξ	14	ЪĊ,	dia	~	6	10	$\equiv$	13	4	~	6	$\equiv$	14	14
otic	17	arse	in ng	2	nth	nth	lth	th	th	th	nth	nth	lth	ith	r 2r	-7	nth	nth	th.	th	lth	th	l th	nth	lth	lth	lth
lec	Ē	ž t	<u>د</u> م	0	Mo	Mo	dor	dor	dor	dor	101	40	Ior	Ior	pei	10	Mo	Mo	Mor	Mor	Mor	dor	40	40	lor	Ior	lor
Ž	l i	gna 50/	tr	-S			~	~	~	~	~	~	2	2	em	S-C			~	~	~	~			$\geq$	2	2
~	4	Sig	gna	AF.											Sec	SAF											
	3	8	Sig	×.											-	<b>v</b> .											
		_															_										
17721	G	-	-	-	-	-	-	-	-	-	-	-	-	$\mathbf{U}$	-	0,1	0,0	0,0	0,0	5,0	0,0	11,7	0,1	0,1	0,1	0,2	0,3
17738	C	-	-	-	-	-	-	-	U	-	-	-	-	-	-	0,0	0,0	0,0	0,1	9,3	1,0	0,0	0,1	0,1	0,1	0,2	0,1
18023	A		-	-	-	-	-	-	-	G	-	-	-	-	-	0,0	0,2	0,1	0,1	0,9	0,2	22,3	0,2	0,0	0,1	0,5	0,4
18877	C	U	-	U	-	U	U	U	U	-	U	U	U	-	-	0,0	47,0	0,0	0,0	6,8	0,0	0,1	2,7	0,2	0,0	0,2	0,1
19186	C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0,1	0,1	0,1	0,0	4,5	0,0	0,5	0,3	0,0	0,2	44,5	0,1
19383	U	- 1	-	-	-	-	-	С	-	-	-	-	-	-	-	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,0	0,2	0,2
19439	C	-	-	-	-	-	-	Α	-	-	-	-	-	-	-	0,1	0,0	0,0	0,0	50,0	0,4	0,5	0,1	0,2	0,0	0,1	0,2
19456	U	·	-	-	-	-	-	С	-	-	-	-	-	-	-	0,0	0,0	0,0	0,0	50,0	0,0	0,2	0,0	0,0	0,1	0,0	0,4
19473	U	·	-	-	-	-	-	С	-	-	-	-	-	-	-	0,1	0,0	1,2	0,0	50,0	0,0	0,2	0,1	0,1	0,3	0,2	0,2
19547	C	_	-	-	-	-	-	-	-	-	-	-	U	-	-	0,0	0,0	0,0	0,0	4.9	0,0	0,0	0,0	0,0	15.2	0.1	0,3
19947	G	-	-	-	-	-	-	U	-	-	-	-	-	-	-	0,0	0,0	0,0	0,0	59,4	0,0	0,2	0,0	0,2	0,0	0,4	0,1
20930	C	-	-	-	-	-	-	-	-	-	U	-	-	-	-	0.1	18.5	0.0	0.0	5.8	0.1	0,0	6.2	0.1	0.0	0.2	0.1
21219	C	- 1	-	-	-	-	-	-	1.1	U	-	-	-	-	-	0.0	0.0	0.0	0.0	0.0	0.0	30.1	0.1	0.0	0.0	0.2	0.1
21232	G	-	-	-	-	-	-	-	-	_	-	-	-	U	-	0,1	0.0	0.0	0.0	0.0	0.0	19,3	0.0	0.1	0.0	0.3	0.3
21575	C	-	-	-	-	$\mathbf{U}$	-	-	-	-	U	U	-	-	-	1.2	44.4	42.4	14.4	8.2	0.0	0.5	4.4	1.2	5.4	0.1	0.5
21765	ΠŪ	- 1	Del	-		-		Del	Del	Del	-	-	Del	Del	Del	0.1	14.7	11.0	38.3	39.2	22.6	22.9	2.1	0.0	21.8	23.7	21.2
21766	A	_	Del	-			-	Del	Del	Del	-		Del	Del	Del	0.0	16.2	11.8	44.0	10.9	1.6	1.1	2.2	0.0	1.2	1.6	1.0
21767			Del	-		-	-	Del	Del	Del			Del	Del	Del	0.1	15.4	11.1	42.8	19.6	0.0	0.0	2 1	0.0	0.0	0.1	0.0
21768	Ă		Del					Del	Del	Del			Del	Del	Del	0.0	15.4	11.2	43.1	10.4	0.0	0.0	21	0.0	0.0	0.1	0.1
21769			Del		-	-		Del	Del	Del	-		Del	Del	Del	0,0	15,4	11.5	43 7	13.7	0.2	0.2	2,1	0.1	0.2	0,1	0.5
2170			Del	-	-	-	-	Dal	Del	Del	-	-	Dal	Del	Del	0.1	18.2	15.2	47.6	9.6	5.6	5.6	3.6	0.0	7.2	6.4	6.5
21001			Del			Del	Del	Del	Del	Del	1.7	Del	Del	Del	Del	0,1	20.3	17.3	19.6	22.1	1 3	43	0.1	2.1	2.5	0,4	1.4
21991			Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del	0,0	20,5	17,5	10,0	22,1	1,5	4,5	0,1	2,1	2,5	2.0	1,4
21992	L L	-	Del	-	-	Del	Del	Del	Del	Del	-	Del	Del	Del	Del	0,1	20,4	16,9	10,1	20,5	1,5	5,0	0,1	2,1	2,5	2,0	12.6
21995		1	Der	-	-	Der	Der	Der	Der	Der		Der	Der	Der	Der	0,1	20,0	10,7	1/,/	1/,0	5,7	18,9	0,1	11,5	7,4	10,7	12,0
22992		A		A	А		-			-	A	A			-	0,5	33,3	22.2	20,6	4,8	0,0	0,0	5,5	0,1	0,0	0,2	0,3
23063		-	U	-	-	-	U	U	U	U	-	-	U	U	U	0,0	50,0	33,3	2/,1	12,4	0,0	0,0	0,/	0,1	0,0	0,4	0,4
23188		-	-	-	-	-	-	-	-	-	U	-	-	-	-	0,0	0,0	0,0	0,0	2,3	0,0	0,1	7,3	0,0	0,1	0,2	0,1
23271		-	Α	-		-	Α	A	A	Α	-		Α	A	A	0,2	15,7	20,0	44,2	4,2	0,0	0,1	5,1	0,0	0,3	0,2	0,2
25277		-	-	-	-	-	-	-	-	-	-	-	-	-	U	0,0	0,0	0,0	0,0	7,9	0,0	0,2	0,2	0,0	0,2	0,1	0,3
23403	A	G	G	G	G	G	G	G	G	G	G	G	G	G	G	0,2	0,0	0,0	0,0	17,4	0,1	0,0	0,1	0,1	0,0	0,1	0,2
23415		-	-	-	-	-	-	-	-	А	-	-	-	-	A	0,1	0,0	0,0	0,0	3,6	1,3	14,0	0,2	0,0	0,1	0,1	0,2
23525		-	-	-	-	-	-	-	-	-	-	-	-	-	U	0,0	0,0	0,0	0,0	2,4	0,0	0,0	0,1	0,1	0,0	0,2	0,2
23598	A	-	-	-	-	-	-	-		-	G	-			-	0,1	0,0	0,1	0,0	1,6	0,0	0,1	49,0	0,1	0,8	0,4	0,0
23604	C	-	A	-	-	-	A	A	A	A	Α	-	A	A	A	0,1	24,8	25,6	37,8	6,0	0,0	0,1	32,7	0,0	0,9	0,6	0,2
23709		-	U	-	-	-	U	U	U	U	-	-	U	U	U	0,1	27,5	28,1	37,8	7,8	0,0	0,1	3,5	0,1	0,1	0,1	0,1
23948	G	-	-	-	С	С	-	-	-	-	C	С	-	-	-	0,0	36,9	37,9	29,0	2,2	0,0	0,2	4,1	0,0	0,0	0,3	0,4
24023		-	-	-	U	U	-	-	-	-	U	U	-	-	-	0,0	43,5	43,5	27,4	2,0	0,0	0,4	5,7	0,3	0,2	0,2	0,7
24506	U	-	G		-	-	G	G	G	G	-		G	G	G	0,0	31,2	25,0	31,9	17,7	0,0	0,1	3,2	0,1	0,0	0,1	0,1
24914	G	-	С	-	-	-	С	С	С	С	-	-	С	С	С	0,0	11,6	24,7	43,9	18,7	0,0	0,1	4,4	0,0	0,0	0,2	0,1
25460	C	-	-	-	-	-	-	U	-	-	-	-	U	-	-	0,2	0,1	49,6	12,9	26,2	0,0	0,3	0,2	0,3	0,1	0,2	0,1
25515	C	-	-	-	-	-	Α	-	Α	-	-	-	-	-	-	0,0	0,0	29,4	31,9	37,6	0,1	0,3	0,0	0,0	0,1	0,2	0,2
25517	C	-	-	-	-	-	-	-	-	U	-	-	-	-	-	0,1	0,0	0,0	0,1	9,9	0,0	37,0	0,1	0,0	0,2	0,1	0,1
25521	C	-	-	-	-	-	-	-	-	-	-	-	-	U	-	0,1	0,1	0,0	0,1	3,1	0,1	27,9	0,2	0,1	0,1	0,9	0,0
25563	G	U	-	U	U	U	-	U	-	-	U	U	U	-	-	0,0	46,2	40,2	20,4	27,4	0,0	0,0	5,6	0,1	0,3	0,2	0,1
25710	C	U	-	U	-	U	-	U	-	-	U	U	U		-	0,1	42,2	34,4	17,6	26,0	0,0	0,1	7,4	0,1	0,0	0,3	0,0
26204	C	-	-	-	-	-	-	U		-	U	-	U	-	-	0,0	23,5	42,9	25,9	28,1	0,0	0,0	3,7	23,0	10,6	0,0	0,0
26681	C	-	-	-		-	-	-	U	-	-	-	-	-	-	3,1	0,1	0,0	0,1	6,2	49,1	0,3	0,2	0,1	0,1	0,0	0,2
26735	C	U	-	U	-	-		-		-	U	U	U	U	-	0,0	37,9	43,5	9,1	8,6	0,0	19,6	17,0	0,0	0,1	0,3	0,2
26819	U	-	-	-	-	-	-	G	-	-	-	-	-	-	-	0,1	0,0	0,0	0,0	35,4	0,1	0,0	0,0	0,1	0,0	0,1	0,3
26835	C	-	-	-	-	-	-	U		-	-	-	-	-	-	0,0	0,0	0,0	0,1	45,4	0,0	0,0	0,1	0,0	0,0	0,2	0,1
26858	C	-	-	-	U	-	U	-	U	U	-	-	-	-	U	0,0	44,1	48,8	13,5	23,6	0,0	28,6	20,2	0,0	0,0	0,1	0,1
26876	U	C	-	С	-	-	-	С	-	-	C	С	С	С	-	0,0	39,2	46,4	12,6	37,2	0,0	22,5	14,7	0,2	0,2	0,2	0,2
26907	C	-	-	-	-	-	-	U	-	-	U	U	U	-	-	0,0	24,9	48,8	43,7	34,9	0,0	0,0	49,1	21,2	15,8	0,6	0,0
26952	A	-	-	-	-	-	-	-	-	-	-	-	-	G	-	0,0	0,0	0,0	0,0	1,5	0,0	28,3	0,0	0,0	0,0	0,1	0,1
27459	G	-	-	-	-	-	-	-	-	U	-	-	-	-	U	0,0	0,0	0,0	0,1	10,0	0,6	11,1	0,1	0,0	0,0	0,0	2,3
27918	A	. –	-	-	-	-	-	-	G	G	-	-	-	G	G	0,3	0,0	0,3	5,1	21,8	0,0	0,0	0,0	0,1	0,0	0,0	0,0
28038	G	-	-	-	-	-	-	-	U	U	-	-	-	U	U	0,0	0,0	1,5	6,4	26,7	0,0	0,0	0,1	0,0	0,1	0,0	0,0
28271	A	-	-	-	U	U	$\mathbf{U}$	U	$\mathbf{U}$	U	U	U	U	$\mathbf{U}$	U	0,1	35,5	0,1	0,0	11,4	0,0	0,1	6,2	0,1	0,3	0,3	0,1
28338	A	-	-	-	-	-	-	-	-	-	-	-	-	-	G	0,1	0,0	0,0	0,0	1,3	0,0	0,0	0,0	0,0	0,0	0,1	0,3
28560	G	-	-	-	U	U	U	U	U	С	U	U	U	U	С	0,1	0,0	0,0	0,1	4,4	0,1	19,2	0,0	0,0	0,0	0,3	0,1
28572	A	- 1	-	-	-	-	-	-	-	G	-	-	-	-	G	0,1	0,0	0,0	0,1	1,2	0,0	21,0	0,0	0,0	0,0	0,1	0,2
28657	C	-	-	-	-	-	-	-	-	-	-	-	-	-	U	0,2	0,0	0,0	0,0	2,5	0,0	0,6	0,1	0,0	0,0	0,1	0,3
28887	C	-	-	-	-	-	-	-	-	U	-	-	-	-	U	0,2	0,0	0,0	0,0	3,5	0,0	15,5	0,2	0,1	0,1	0,4	0,0
28975	G	C	-	С		С	С	С	С	С	С	С	С	С	С	0,4	32,8	0,0	0,0	16,6	0,0	5,5	7,3	0,0	0,1	0,1	0,3
28977	C	-	U	-	U	-	-	-	-	-	-	-	-	-	-	0,0	45,1	2,5	0,0	2,8	0,7	0,0	7,3	0,0	0,0	0,2	0,1
29242	A	-	-	-	U	-	-	-	-	-	-	-	-	-	-	0,1	47,9	0,2	0,1	2,0	0,0	0,1	5,8	0,0	0,2	0,3	0,3
29399	G	A	-	Α	Α	Α	Α	Α	Α	А	Α	Α	Α	Α	А	0,0	0.1	0.0	0.0	9.3	0.0	0.0	0.0	0.0	0.1	0.1	0.5
29445	C	-	-	-	-	U	-	U	-	-	-	U	U	-	-	0.0	0.1	31.6	30.4	16.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0
29743	l c	-	-	-	-	-	_	-	-	-	-	-	U	_	-	0.1	0.0	0,0	0,0	32.1	0.0	0.0	0.1	0.0	13.5	0.1	0,1

### 107 SUPPLEMENTARY TABLES

108

#### 109 Supplementary Table S1. List of GISAID identifiers for sequences used in the present

- 110 **study.**
- 111 All genomes analyzed here were obtained in our laboratory (University hospital institute

112 Méditerranée Infection, Marseille, France). The GISAID sequence database is accessible at:

113 (https://www.gisaid.org/) [3].

Source sample	GISAID identifier
Respiratory samples	
	EPI_ISL_10816729
	EPI_ISL_10816731
	EPI_ISL_10816733
	EPI_ISL_10816740
	EPI_ISL_10816742
	EPI_ISL_10816743
	EPI_ISL_10816744
	EPI_ISL_11030507
	EPI_ISL_2757096
	EPI_ISL_3054898
	EPI_ISL_3054899
	EPI_ISL_3055037
	EPI_ISL_3055223
	EPI_ISL_3055225
	EPI_ISL_3055227
	EPI_ISL_3055234
	EPI_ISL_3055235
	EPI_ISL_3830105
	EPI_ISL_3830215
	EPI_ISL_3831874
	EPI_ISL_3933559
	EPI_ISL_3933565
	EPI_ISL_3933569
	EPI_ISL_3933571
	EPI_ISL_3933572
	EPI_ISL_3934656
	EPI_ISL_3934682
	EPI_ISL_3934683
	EPI_ISL_4394365

115Supplementary Table S1 - continued116

	EPI_ISL_4944362
	EPI_ISL_4944364
	EPI_ISL_4951784
	EPI_ISL_4951785
	EPI_ISL_6332079
	EPI_ISL_6737742
	EPI_ISL_7376142
	EPI_ISL_7376355
	EPI_ISL_8321213
	EPI_ISL_8321223
	EPI_ISL_8321228
	EPI_ISL_8321229
	EPI_ISL_8321241
	EPI_ISL_8321242
	EPI_ISL_8321256
	EPI_ISL_8709907
	EPI_ISL_8709910
	EPI_ISL_8711731
	EPI_ISL_9773781
	EPI_ISL_9774389
	EPI_ISL_9774894
	EPI_ISL_9774895
Culture supernatants	
	EPI ISL 10816730
	EPI_ISL_10816732
	EPI_ISL_10816734
	 EPI_ISL_10816735
	EPI_ISL_10816738

117

#### 118 **References**

- La Scola, B.; Le Bideau, M.; Andreani, J.; et al. Viral RNA load as determined by cell
   culture as a management tool for discharge of SARS-CoV-2 patients from infectious
   disease wards. *Eur J Clin Microbiol Infect Dis.* 2020, *39*, 1059-1061.
- 122 2. Colson, P.; Fournier, PE.; Chaudet, H.; et al. Analysis of SARS-CoV-2 Variants From
- 123 24,181 Patients Exemplifies the Role of Globalization and Zoonosis in Pandemics. *Front*
- 124 *Microbiol.* **2022**, *12*, 786233. doi: 10.3389/fmicb.2021.786233.

- 125 3. Alm, E.; Broberg, EK.; Connor, T.; et al. Geographical and temporal distribution of
- 126 SARS-CoV-2 clades in the WHO European Region, January to June 2020. *Euro Surveill*.
- 127 **2020**, *25*, 2001410.
- 128
- 129